Tag Archives: NIH

NIH’s change to indirect costs as an opening for research enterprise change

A few days ago, Chris Newfield published an article on his Remaking blog on the proposed NIH cuts to university indirect costs. Now, Chris is the most knowledgeable person on university financing who is willing to speak openly about how … Continue reading

Posted in Policy, Projects | Tagged , , , | Leave a comment

NIAID botches Bayh-Dole

This will be a bit of a long ride. Buckle up. In 2011, the US Supreme Court ruled in Stanford v Roche that the Bayh-Dole Act does not vest title to inventions made in federally supported work with the nonprofit … Continue reading

Posted in Bayh-Dole, Bozonet | Tagged , , , | Comments Off on NIAID botches Bayh-Dole

Why the NIH fuss with Moderna over inventorship doesn’t matter, but does

The New York Times ran a story today that Moderna and the NIH are having a spat over inventorship on a patent application covering aspects of the Moderna mRNA vaccine. The N.I.H. had been in talks with Moderna for more … Continue reading

Posted in Bayh-Dole, Bozonet, Policy | Tagged , , , , | Comments Off on Why the NIH fuss with Moderna over inventorship doesn’t matter, but does

More NIH Bayh-Dole Slop

The NIH cannot get Bayh-Dole right. Or maybe the NIH doesn’t want to get Bayh-Dole right. Here’s an NIH announcement from 2018 about policy changes, “Notice Regarding 2018 Bayh-Dole Act Final Rule – Rights to Federally Funded Inventions and Licensing … Continue reading

Posted in Bayh-Dole | Tagged , , | Comments Off on More NIH Bayh-Dole Slop

“Promote” in Bayh-Dole, 4

In arguing in Public Citizen v NIH that secret exclusive deals were the only way the NIH could fulfill its public mission–or at least the mission of its patent licensing office–the NIH produced some interesting metrics. In 2000, the NIH … Continue reading

Posted in Bayh-Dole, Bozonet | Tagged , , , , , , , | Comments Off on “Promote” in Bayh-Dole, 4

What the NIH says about Bayh-Dole, 3

Now we arrive at the source of the NIH’s conflation in its most recent “background” misrepresentation of Bayh-Dole. We are deep into the federally owned invention side of Bayh-Dole, section 209(a), in a list of the requirements that must be … Continue reading

Posted in Bayh-Dole, Commons | Tagged , , | Comments Off on What the NIH says about Bayh-Dole, 3

What the NIH says about Bayh-Dole, 2

We are working through the NIH’s most recent misrepresentation of the Bayh-Dole Act. In the first part of this effort, we looked at the NIH’s bungling of the basic premise of Bayh-Dole and the concept of practical application. Bayh-Dole’s first … Continue reading

Posted in Bayh-Dole, Commons, Open Source | Tagged , , , , | Comments Off on What the NIH says about Bayh-Dole, 2

What the NIH says about Bayh-Dole, 1

The NIH has published comments on the NIST changes to the regulations that implement the Bayh-Dole Act and the standard patent rights clause. Jamie Love at Knowledge Ecology International calls out in a tweet a passage in the “Background” section in … Continue reading

Posted in Bayh-Dole, Open Source, Policy | Tagged , , , , | Comments Off on What the NIH says about Bayh-Dole, 1

Bayh-Dole preempts NIH policy on improper financial gain

Here’s a passage from the NIH Grants Policy Statement (Part I, Chapter 4): NIH grants are subject to requirements intended to ensure that recipient organizations handle their Federal awards responsibly. Recipients are required to adopt and enforce policies that minimize … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , , | Comments Off on Bayh-Dole preempts NIH policy on improper financial gain

Exceptional Circumstances in Bayh-Dole, 6

You may think it’s mean of me to pick on Dr. Thomas for a talk that’s a decade old, and presented before the Stanford v Roche case was decided. If so, then you might want to consider the Public Health … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on Exceptional Circumstances in Bayh-Dole, 6